Crossject (PA:ALCJ) develops new therapeutic entities (proprietary versions of generic drugs) to be used with its needle-free injection system, ZENEO. ZENEO is a drug delivery and manufacturing platform for multiple potential products, including biologics and vaccines, and has the potential to improve therapeutic delivery, safety, patient compliance and comfort for many conditions. In November, Crossject received a €6.7m grant to expand development and manufacturing capabilities to include new ZENEO products for drug overdose, Parkinson’s disease and epileptic seizures.
Safer and easier = better compliance
Injectable pharmaceuticals have a number of therapeutic advantages, including quicker onset, good absorption and a very long duration of action with certain formulations. At the same time, without proper medical supervision injections can be error-prone, painful and patient compliance is often an issue. A 2014 study by the University of Texas showed that fewer than 20% of patients used their epipens correctly. Crossject's needle-free, pre-filled, single-use ZENEO injection systems are designed to be self-administered and can be tailored to deliver drugs via intradermal, subcutaneous and intramuscular routes, allowing the system to be used in a broad range of indications. ZENEO has been tested in more than 10,000 humans, including seven preclinical and eight clinical trials. ZENEO’s advantages vs other needle-free systems include extensive clinical studies showing reliability and safety and ability for the ZENEO system to be used with many types of molecules.
To read the entire report Please click on the pdf File Below